Glimepiride is a sulfonylurea used in the treatment of type 2 diabetes mellitus; unlike similar medications such as metformin, glimepiride promotes the secretion of insulin and increases the expression of IGF, having the potential to promote tumorigenesis as a single agent through activation of mitogen-activated protein kinase and PI3K–Akt–mTOR pathways [48]. This evidence concerns the gene IGF1 and type 2 diabetes mellitus.